Skip to main content

Raymond K. Cross, MD

Academic Title:


Primary Appointment:


Additional Title:

Director, Inflammatory Bowel Disease Program



Phone (Primary):

(410) 706-3387 (office)


(410) 706-4330

Education and Training

Dr. Cross received his undergraduate degree from Washington and Jefferson College in Washington, Pennsylvania, and his medical degree from the University of Pittsburgh School of Medicine in Pittsburgh, Pennsylvania. He completed his postgraduate training in Internal Medicine at the University of Maryland and Baltimore VA Medical Centers in Baltimore, Maryland, where he was chosen as Chief Resident. He performed his Gastroenterology fellowship also at the University of Maryland and Baltimore VA Medical Centers in Baltimore. In addition, Dr. Cross has obtained a Master of Science degree in Clinical Research at the University of Maryland School of Medicine, Department of Epidemiology and Preventive Medicine, in Baltimore. 


K. Cross, Jr., M.D.,M.S. is a board certified Gastroenterologist and Professor of Medicine, Division of Gastroenterology and Hepatology, at the University of Maryland School of Medicine in Baltimore, Maryland. He also serves as Director of the Inflammatory Bowel Disease Program at the University of Maryland School of Medicine in Baltimore (UMB) and is Co-Director of the Digestive Health Center at the University of Maryland Medical Center in Baltimore.

Dr. Cross is a Fellow of the American Gastroenterological Association and a member of the American College of Gastroenterology and Crohn’s and Colitis Foundation of America (CCFA). He is the past Chair of the Patient Education Committee and current Chair of the Clinical Awards Committee of the CCFA. He is also a member of Mission Committee of the Maryland and Delaware Chapter of the CCFA.

Research/Clinical Keywords

Outcomes research, clinical trials, telemedicine to improve care in patients with inflammatory bowel disease (IBD)

Highlighted Publications

1. Cross, RK and Wilson, KT. Nitric oxide in Inflammatory Bowel Disease. Inflamm Bowel Dis 2003;9:179-89.

2. Gobert, AP, Cheng, Y., Akhtar, M., Mersey, BD, Blumberg, DR, Cross, RK, Chaturvedi, R., Drachenberg, CB, Boucher, JL, Hacker, A., Casero, RA, Jr., and Wilson, KT. Protective role of arginase in a mouse model of colitis. J Immunol 2004;173:2109-17.

3. Cross RK, Wilson, KT, and Binion, DG. Polypharmacy and Crohn's disease. Aliment Pharmacol Ther 2005;21:1211-6

4. Cross RK, Wilson, KT, and Binion, DG. Narcotic use in patients with Crohn's disease. Am J Gastroenterol 2005;100(10):2225-9.

5. Cross RK, Arora, M, and Finkelstein, J. Acceptance of telemanagement is high in patients with inflammatory bowel disease. J Clin Gastroenterol 2006;40(3):200-8.

Additional Publication Citations

  1. Cross RK, Jung, C, Wasan, S, Joshi, G, Sawyer, R, and Roghmann, MC. Racial Differences in Disease Phenotypes in Patients With Crohn's Disease. Inflamm Bowel Dis 2006;12(3):192-198.
  2. Castro, HK, Cross, RK, and Finkelstein, J. Using a Home Automated Telemanagement System (HAT): Experiences and Perceptions in Patients with Inflammatory Bowel Disease. AMIA Annu Symp Proc 2006;872.
  3. Cross, RK and Finkelstein, J. Feasibility and Acceptance of a Home Telemanagement System in Patients with Inflammatory Bowel Disease: A 6-Month Pilot Study. Dig Dis Sci 2007;52(2):357-364.
  4. Donovan, M, Lunney, K, Carter-Pokras, O, and Cross, RK. Prescribing Patterns and Awareness of Adverse Effects of Infliximab: A Health Survey of Gastroenterologists. Dig Dis Sci. Aug 2007;52(8):1798-1805.
  5. Cross, RK, Lapshin, O, and Finkelstein, J. Patient Subjective Assessment of Drug Side Effects in Inflammatory Bowel Disease. J Clin Gastroenterol. 2008;42(3):244-51
  6. Flasar, MH, Johnson, T, Roghmann, MC, and Cross, RK. Disparities in the use of immunomodulators and biologics for the treatment of inflammatory bowel disease: A retrospective cohort study. Inflamm Bowel Dis. 2008;14(1):13-9
  7. Flasar, M, Quezada, S, Bijpuria, P, Wu, Roger, and Cross, RK. Racial Differences in Extent, Severity, and Extraintestinal Manifestations in Patients with Ulcerative Colitis: A Retrospective Cohort Study. Dig Dis Sci. 2008;53(10):2754-2760
  8. Joshi, G, Cross, RK, and Flasar, MH. Race and Inflammatory Bowel Disease. Practical Gastroenterology. 2009;33(1):23-33.
  9. Warren, JW, Howard, FM, Cross, RK, Good, J, Weissman, M, Wesselmann, U, Langenberg, P, Greenberg, P, and Clauw, D. “Antecedent non-bladder syndromes in a case control study of interstitial cystitis/painful bladder syndrome”. Urology. 2009;73(1):52-7.
  10. Cross, RK, Cheevers, N, and Finkelstein, J. Home Telemanagement for Patients with Ulcerative Colitis (UC HAT). Dig Dis Sci 2009;54(11):2463-2472.
  11. St. Charles, M, Weiss Smith, SR, Beardsley, R, Fedder, DO, Carter-Pokras, O, and Cross, RK. Gastroenterologists Prescribing of Infliximab: A National Survey. Inflamm Bowel Dis. 2009;15(10)1467-75.
  12. Cross R and Finkelstein, J. Challenges in the design of a Home Telemanagement Trial for patients with ulcerative colitis. Clin Trials 2009;6(6)649-57.
  13. Samimi, R, Flasar, MH, Kavic, S, Tracy, K, and Cross, RK. Outcome of Medical Treatment of Stricturing and Penetrating Crohn’s Disease: A Retrospective Study. Inflamm Bowel Dis. 2010;16(7):1187-1194.
  14. Cross, RK, Cheevers, N, Rustgi, A, Langenberg, P, and Finkelstein, J. A Randomized, Controlled Trial of Home Telemanagement in Patients with Ulcerative Colitis (UC HAT). Inflamm Bowel Dis 2012;18(6):1018-1025.
  15. Cross, RK. Application of Telemedicine for Inflammatory Bowel Disease: Review of the Literature and Future Implications. J Gastrointest Digest Sys. October 2011;1(e102).
  16. Flasar, MH, Cross, RK, and Doman, DB. Current and Future Role of Ulcerative Colitis Serogenomics. Gastroenterology and Hepatology. November 2011;7(11):720-727.
  17. Patil, SA, Rustgi, A, Quezada, SM, Flasar, MH, Vandermeer, F, and Cross RK. Anti-TNF Therapy is Associated with Decreased Imaging and Radiation Exposure in Patients with Crohn’s Disease. Inflamm Bowel Dis. 2013;19(1):92-98.
  18. Quezada, SM and Cross, RK. Association of Age at Diagnosis and Ulcerative Colitis Phenotype. Dig Dis Sci. 2012;57(9):2402-2407.
  19. Faust, AH, Halpern, LF, Danoff-Burg, S, and Cross, RK. Psychosocial Factors Contributing to Inflammatory Bowel Disease Activity and Health-Related Quality of Life. Gastroenterology & Hepatology. March 2012;8(3):1-9.
  20. McLean, LP, Shea-Donahue, T, and Cross, RK. Vedolizumab for the Treatment of Ulcerative Colitis and Crohn’s Disease. Immunotherapy. 2012;4(9):883-898.
  21. Patil, S and Cross, RK. Where We’re Going, We Don’t Need Appointments: the Future of Telemedicine in IBD. (Summary of Krier, M, Kaltenbach, T, McQuaid, K, et al. Potential Us of telemedicine to provide outpatient care for inflammatory bowel disease. Am J Gastroenterol. 2011;106:2063-7). Inflamm Bowel Dis. 2012;18(11):2199-2200.
  22. Quezada, SM, Steinberger, EK, and Cross, RK. Association of Age at Diagnosis and Crohn’s Disease Phenotype.  Age Ageing. August 2012;0:1-4.
  23. Patil, SA, Rustgi, A, Langenberg, P, and Cross, RK. Comparative Effectiveness of Anti-TNF Agents for Crohn’s Disease in a Tertiary Referral IBD Practice. Dig Dis Sci. 2013;58(1):209-215.
  24. Ghazi, LJ, Patil, SA, Rustgi, A, Flasar, MH, Razeghi, S, and Cross, RK. Step Up versus Early Biologic Therapy for Crohn’s Disease in Clinical Practice. Inflamm Bowel Dis. 2013;19(7):1397-1403.
  25. Syed, A, Cross, RK, and Flasar, MH. Anti-Tumor Necrosis Factor Therapy is Associated with Infections after Abdominal Surgery in Crohn’s Disease Patients. Am J Gastroenterol. 2013;108(4):583-593.
  26. Patil, SA and Cross, RK. Update in the Management of Extraintestinal Manifestations of Inflammatory Bowel Disease. Curr Gastroenterol Rep 2013;15(3):314.
  27. McLean, LP and Cross, RK. “Adverse Events in IBD: To Stop or Continue Immune Suppressant and Biologic Treatment”. Expert Rev Gastroenterol Hepatol. 2014;8(3):223-240.
  28. Patil, SA and Cross, RK. “Can You Hear Me Now? Frequent Telephone Encounters for Management of Patients with Inflammatory Bowel Disease. (Summary of Ramos-Rivers, CM, Regueiro, M, Vargas, EJ et al. Association Between Telephone Activity and Features of Patients with Inflammatory Bowel Disease. Clin Gastroenterol Hepatol). Clin Gastroenterol Hepatol. 2014;12(6):995-996. 
  29. Ghazi, LJ, Lydecker, AD, Patil, SA, Rustgi, A, Cross, RK, and Flasar, MH. Racial Differences in Disease Activity and Quality of Life in Patients with Crohn’s Disease. Dig Dis Sci. 2014;50(10):2508-2513.
  30. Osterman, MT, Aberra, FN, Cross, R, Liakos, S, McCabe, R, Shafran, I, Wolf, D, Hardi, R, Nessel, L, Brensinger, C, Gilroy, E, and Lewis, JD. A Randomized Controlled Trial of Mesalamine Dose Escalation for Ulcerative Colitis in Remission. Clin Gastroenterol Hepatol. 2014;12(11):1887-93.
  31. Flasar, MH and Cross, RK. What is the need for comparative effectiveness studies in IBD? Expert Rev Gastroenterol Hepatol. Early online, 2014;8(8):851-4.
  32. Zullow, S, Flasar, MH, Greenberg, D, Tracy, JK, Rustgi, A, and Cross, RK. A Health Survey of Gastroenterologist Prescribing Practices of Adalimumab for Treatment of Crohn’s Disease: Final Results. Gastroenterology & Hepatology. 2014;10(8):1-7.
  33. Regueiro, MD, Greer, JB, Binion, DG, Schraut, WH, Goyal, A, Keilo, DJ, Cross, RK, Williams, ED, Herfarth, HH, Siegel, CA, Oikonomou, I, Brand, MH, Hartman, DJ, Tublin, ME, Davis, PL, Baidoo, L, Szigethy, E, and Watson, AR. The Inflammatory Bowel Disease Live Interinstitutional and Interdisciplinary Videoconference Education (IBD LIVE) Series. Inflamm Bowel Dis. 2014;20(10):1687-95.
  34. Ghazi, LJ and Cross, RK. The Role of Telemedicine and E-Health in the Management of Inflammatory Bowel Disease: Improving Patient Outcomes. Smart Homecare Technology and Telehealth. 2015;3:17-24.
  35. Quezada, SM, Rustgi, A, Jambaulikar, GD, and Cross, RK. Differential Response to Microbial Antigens by Age of Diagnosis in Patients with Crohn’s Disease. Clin Exp Gastroenterol. 2015;8:169-74.
  36. Le, P, Greer, J, Oikonomou, I, Schraut, W, Siegel, C, Cross, RK, Holubar, S, Tinsley, A, Koltun, W, Binion, D, Regueiro, M. Previous Cancer in a Patient with Crohn’s Disease: Is It Appropriate to Use Biologics and Immunosuppressants for IBD Treatment? Inflamm Bowel Dis. 2015; 21(6): 1401-6.
  37. Cross, RK, Jambaulikar, Guruprasad, Langenberg, P, Tracy, JK, Collins, JF, Katz, J, Regueiro, M, Schwartz, DA, and Quinn, CC. TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD): Design and Implementation of Randomized Clinical Trial. Contemp Clin Trials. 2015;132:132-44.
  38. George, LA, Gadani, A, Cross, RK, Jambaulikar, G, and Ghazi, LJ. Psoriasiform Skin Lesions are Caused by Anti-TNF Agents used for the Treatment of Inflammatory Bowel Disease. Dig Dis Sci. 2015; 60(11): 3424-30.
  39. Ghazi, LJ, Patil, SA, and Cross, RK. Sexual Dysfunction in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015; 21(4):939-47.
  40. Hagan, M and Cross, RK. Vedolizumab for Treating Crohn’s Disease and Ulcerative Colitis. Expert Opin Drug Saf. 2015; 14(9): 1-8
  41. Huang, C, Haritunians, T, Okou, DT, Cutler, DJ, Zwick, ME, Taylor, KD, Datta, LW, Maranville, JC, Alexander, JS, Baldassano, RN, Cho, JH, Cross, RK, Dassopoulus, T, Dhere, TA, Duerr, RH, Hanson, JS, Hou, JK, Hussain, SZ, Isaacs, KL, Kachelries, KE, Kader, H, Kappelman, M, Katz, J, Kirschner, BS, Kummerle, JF, Kumar, A, Kwon, JH, Lazarev, M, Mannon, P, Moulton, DE, Osuntokun, BO, Patel, A, Rioux, JD, Rotter, JI, Saeed, S, Scherl, EJ, Silverberg, MS, Silverman, A, Targan, SR, Valentine, J, Wang, M, Zonca, M, Simpson, CL, Bridges, SL, Kimberly, RP, Rich, SS, Di Rienzo, A, Kao, LWH, McGovern, DPB, Brant, SR, and Kugathasan, S. Characterization of genetic loci that affect suspectibility to inflammatory bowel disease in African Americans. Gastroenterology. 2015; 149(6): 1575-86.
  42. Stoddard, PB, Ghazi, LJ, Wong-You-Cheong, J, Cross, RK, and Vandermeer, FQ. Magnetic Resonance Enterography: State of the Art. Inflamm Bowel Dis 2015;21(1):229-39.
  43. Cross, RK. Which patients with inflammatory bowel disease should receive combination therapy? Expert Rev Gastroenterol Hepatol. 2015; 9(6): 715-717.
  44. Flasar, M, Chao, J, Ozbay, AB, Skup, M, Lu, M, and Cross, R. Racial differences in the use of biologic and immunomodulator in Crohn’s disease in a Medicaid population. Inflamm Bowel Dis. 2016; 22(5): 1056-64.
  45. Sunseri, WM, Kugathasan, S, Keljo, DJ, Greer, JB, Ranganathan, S, Cross, RK, Siegel, CA, and Regueiro, MD. IBD LIVE Case Series-Case 3: Very Early-Onset Inflammatory Bowel Disease: When Genetic Testing Proves Beneficial. Infamm Bowel Dis. 2015; 21(12): 2958-68.
  46. Gulati, A, Clarke, K, Greer, J, Binion, D, Brand, M, Farraye, F, Cross, R, Baidoo, L, Schraut, W, Hartman, D, Regueiro, M. IBD Live Case Series-Case 4: Worms in IBD: Friend or Foe. Inflamm Bowel Dis. 2016; 22(6): 1462-72.
  47. McLean, LP and Cross, RK. Integrin Antagonists as Potential Therapeutic Options for the Treatment of Crohn’s Disease. Expert Opinion on Investigational Drugs. 2016; 25(3): 263-273.
  48. McLean, LP and Cross, RK. Pharmacodynamic assessment of vedolizumab for ulcerative colitis. Expert Opinion on Drug Metabolism and Toxicology. 2016; DOI: 10.1080/17425255.2016.1181171.
  49. Quezada, SM, Briscoe, J, and Cross, RK. Complementary and Alternative Medicine. Inflamm Bowel Dis. 2016; 22(6): 1523-30.
  50. Afzali, A and Cross, RK. Racial and ethnic minorities with Inflammatory Bowel Disease in the United States: A systematic review of disease characteristics and differences. Inflamm Bowel Dis. 2016; 22(8): 2023-40.  
  51. Quezada, SM, Langenberg, P, and Cross, RK. Cigarette smoking adversely affects disease activity and disease-specific quality of life in patients with Crohn’s disease at a tertiary referral center. Clinical and Experimental Gastroenterology. In press.